- Research article
- Open Access
- Open Peer Review
Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays
© Choi et al; licensee BioMed Central Ltd. 2008
- Received: 29 May 2008
- Accepted: 07 November 2008
- Published: 07 November 2008
Recent studies have shown similarities between schizophrenia and bipolar disorder in phenotypes and in genotypes, and those studies have contributed to an ongoing re-evaluation of the traditional dichotomy between schizophrenia and bipolar disorder. Bipolar disorder with psychotic features may be closely related to schizophrenia and therefore, psychosis may be an alternative phenotype compared to the traditional diagnosis categories.
We performed a cross-study analysis of 7 gene expression microarrays that include both psychosis and non-psychosis subjects. These studies include over 400 microarray samples (163 individual subjects) on 3 different Affymetrix microarray platforms.
We found that 110 transcripts are differentially regulated (p < 0.001) in psychosis after adjusting for confounding variables with a multiple regression model. Using a quantitative PCR, we validated a set of genes such as up-regulated metallothioneins (MT1E, MT1F, MT1H, MT1K, MT1X, MT2A and MT3) and down-regulated neuropeptides (SST, TAC1 and NPY) in the dorsolateral prefrontal cortex of psychosis patients.
This study demonstrates the advantages of cross-study analysis in detecting consensus changes in gene expression across multiple microarray studies. Differential gene expression between individuals with and without psychosis suggests that psychosis may be a useful phenotypic variable to complement the traditional diagnosis categories.
- Gene Ontology
- Bipolar Disorder
- Microarray Study
- Psychotic Feature
Kraepelin's 1896 dichotomous classification of functional psychoses into dementia praecox (schizophrenia) and manic-depressive insanity (bipolar disorder) is well known and has dominated most diagnostic systems in psychiatry. Less well known is the fact that two decades later, Kraepelin himself questioned the validity of his classificatory system, noting that "it is becoming increasingly clear that we cannot distinguish satisfactorily between these two illnesses and this brings home the suspicion that our formulation of the problem may be incorrect." [1, 2] In recent years, increasing number of observers have shared Kraepelin's doubts, with some proposing instead a continuum hypothesis [3, 4]. Clinically, there is much overlap of symptoms, and the intermediate category of schizoaffective disorder may imply an artificial preservation of the dichotomy between these two diagnoses . The clinical gulf between individuals with bipolar II and those with bipolar I with psychotic features is marked, whereas the latter often resemble individuals with schizophrenia quite closely. Epidemiologically, there is also some overlap, especially in so far as both have a winter-spring seasonal birth excess [6, 7].
Genetically, it has been said that "accumulating evidence supports the existence of an overlap in genetic susceptibility across the traditional Kraepelinian divide" ; this has been reported for family studies, linkage studies, and candidate genes such as G72, NRG1, dysbindin, COMT, BDNF, and DISC1 [9–12]. An overlap for some neuropsychological dysfunctions, such as working memory , has also been reported, although individuals with bipolar disorder are less severely impaired . This suggests that working memory dysfunction may be closely related to psychotic features in individuals with schizophrenia and with bipolar disorder.
Neuropathologically, an overlap in findings between schizophrenia and bipolar disorder has also been noted, both neurochemically  and structurally . As was true for the neuropsychology findings, individuals with bipolar disorder are structurally less severely impaired. Neuropathological studies that have divided bipolar patients into those with and without psychotic features have reported that the former are more closely related to schizophrenia than the latter . This last observation suggests that an important variable in categorizing seriously mentally ill individuals may be the presence or absence of psychotic features. To date, most studies of gene expression in schizophrenia and bipolar disorder have used the traditional Kraepelinian classification. We, therefore, decided to reanalyze a set of microarray studies, dividing the individuals within each study into those with and without psychotic features.
Although genome-wide expression studies of psychiatric disorders have been published, there have been inconsistent findings among previous studies possibly due to several factors including: relatively small sample sizes, inappropriate p-value and fold change criteria, and failure to adjust for potential confounding variables. In order to address these issues, we performed a cross-study analysis of 7 microarray datasets using the subjects with and without psychotic features from the two post-mortem brain collections of the Stanley Medical Research Institute (SMRI). The microarray datasets of the prefrontal cortex with three Affymetrix platforms (hgu133A, hgu133 2.0+ and hgu95Av2) were used for this cross-study analysis.
Post-mortem brain tissues
Two post-mortem brain collections from the SMRI have been made available to researchers worldwide. The first, the Neuropathology Consortium, has 60 individual subjects, with multiple brain regions per subject. The details of the sample collection have been described previously . Notable exclusion criteria include: age>65 years, poor quality mRNA, and significant structural brain pathology on post-mortem examination. These samples are matched for age, gender, race, pH, post-mortem interval (PMI), side of the brain and mRNA quality. For microarray studies using this collection, tissue samples from the prefrontal cortex (Brodmann area 46/10, 6 and 8/9) were provided to individual investigators, who then performed the RNA extraction and experiment.
The second, the Array Collection, consists of 105 individual subjects, with multiple brain regions per subject. Exclusion criteria are similar to those for the Neuropathology Consortium. For this collection, dorsolateral prefrontal cortex (Brodmann area 46) was used for the microarrays. In contrast to the Neuropathology Consortium, the SMRI performed the RNA extraction for the Array Collection tissues. Briefly, tissue was homogenized in Trizol; nucleic acid was separated with chloroform at high speed centrifugation; and RNA was then precipitated with isopropyl alcohol and washed with 70% alcohol. Pellets of RNA were resuspended in DEPC water. The quality of RNA was assessed using an Agilent bioanalyzer 2100 (Agilent, Foster City, CA). RNA processing and microarray data generation was performed by the individual investigators at their own facilities. RNA processing protocols were generally those recommended by the Affymetrix microarray manufacturer.
For the current analysis, the subjects in the Neuropathology Consortium and the Array Collection were divided into two groups. Those with psychosis (N = 81) included those with schizophrenia and those with bipolar disorder with psychotic features. The non-psychotic controls (N = 82) included those with bipolar without psychotic features, those with depression, and the unaffected controls. Two cases with bipolar disorder were excluded due to insufficient information on psychotic features.
Quality control of microarray data
All microarray raw data (cel files) were transformed using the Robust Multichip Average (RMA) normalization algorithm. The importance of quality control (QC) measures in microarray studies, including pre-chip (RNA quality of samples) and post-chip outcomes of the data, has been described previously . We have performed a series of QC analyses to identify and remove microarray chip outliers before conducting statistical analysis on individual studies and on combined studies. Detailed QC procedures are described in our previous publications [20, 21]. Briefly, each microarray chip was subjected to Affymetrix QC metrics for chip-level parameters such as scale factor, probe perfect match/mismatch difference counts, percent present calls, control gene (GAPDH and beta-actin) 5'/3' ratios and average correlation with respect to the reference distribution for those parameters across the arrays. Although no hard cutoffs were applied for each of the QC metrics, we examined the distribution of the metrics to determine whether samples appeared to be outliers.
Analysis of microarray studies
The cross-study analysis includes 7 Affymetrix microarrays that were completed and provided to the SMRI from each investigator. The studies were coded as 1, 2, 3, 4, 5, 7 and 14 for the purpose of cross-study analysis to focus on the overall results and findings of the larger investigation, and also for the consistency with the SMRI online genomics database http://www.stanleygenomics.org. Names of the investigators involved in microarray studies are as follows: Study 1: Altar A, Study 2: Altar C, Study 3: Bahn, Study 4: Chen, Study 5: Dobrin, Study 7: Kato, Study 14: Sklar A.
It is important to note that studies based on a common brain collection will have overlap in terms of subjects, thus the combined analysis on these studies are not completely independent. As a result, the degrees of freedom (df) can be over-estimated and the resulting p-values may be insufficiently stringent. In order to adjust for this lack of independence, a permutation method was used to identify a correction factor that adjusts the naïve df for the calculated p-value to a lower value (and subsequently higher p-value) at the point where the percentage of differentially expressed genes is equal to the selected alpha level (i.e. 5% differentially expressed genes found at p < 0.05) based on random data. This method used 7 microarray studies where both individual and cross-study analyses were computed for each iteration, for 100 total iterations, similar to our previous study .
For each iteration, the columns of each of 7 microarray data matrices were randomly shuffled to remove class memberships. Then, both individual study and cross-study analyses were computed on these permuted studies. Next, we calculated the cross-study p-values for the genes using df correction factor values starting at 0 and going up to 8 by increments of 0.2. For example, if the naïve df for gene X is 5, then using a correction value of 1.2, the adjusted df would be 3.8 and the adjusted p-value is calculated using this adjusted df. The number of genes at p < 0.05 was summated using each incremental df correction factor for 100 total permutations and the df (based on the naïve df minus the correction factor) that provided a median of 5% of the genes (p < 0.05) was selected. Genes where the difference between the naïve df and the correction factor was less than or equal to 0 were not counted in the gene percentages. This selected correction factor was then applied to the naïve df for each gene in the original data to provide adjusted p-values for each gene. We acknowledge the dependency between these studies where certain subjects are shared; however, after correcting for this over-estimated df, we found that our results are more powered to demonstrate consensus fold changes as compared to a single study.
Individual study analysis
First, each demographic and clinical variable was assessed using a multiple regression model within each study. We identified probe sets that were significantly correlated with individual variables, where significance was defined as p < 0.01 and fold change >1.3 (the criteria that widely used in the previous brain microarray studies). For comparison of effect sizes, all demographics were analyzed using two levels. Continuous variables and ordered categorical variables were cut at values as close as possible to the median (e.g. continuous: PMI>30 vs. PMI<30; categorical: Heavy drug use vs. All lower levels of drug use) for the regression analysis. Demographic variables were assessed using both non-psychotic controls and psychosis subjects, while disease-specific variables were analyzed within the disease group to avoid the confounding of demographic effects and disease effects.
The following demographic variables were considered for all subjects: age, gender, PMI, brain pH, side of the brain, smoking at time of death, and sudden death. For subjects with psychosis, the following variables were considered: disease severity, heavy alcohol use, heavy drug use, suicide status, antipsychotic use, antidepressant use, and mood stabilizer use. Following the demographic analyses, the psychosis class was analyzed to identify a list of discriminating genes adjusted for the demographic terms (we used a common set of demographics for all analyses, including brain pH, PMI, lifetime antipsychotics, bipolar disorder, mood stabilizer lithium, lifetime alcohol, lifetime drug) or markers indicative of disease between the psychosis subjects and non-psychotic controls. The multiple regression analysis provided an adjusted fold change, standard error (SE), and p-value for each gene in each study.
The cross-study comparisons are based on scaled representations of individual study-level analysis across studies to extract the biological patterns and relationships. For the gene level analysis, consensus fold change was calculated for each gene based on a weighted combination of the individual fold changes and the SEs for the Affymetrix probe sets that map to each gene across the studies. Weights were determined in a probe set specific manner to account for the different levels of precision associated with each probe set that map to a given gene across the platforms. The weights were equal to 1/SEi, where SEi is the standard error of the ith probe set for the gene across all the studies. For the Gene Ontology (GO) analysis, GO association to disease was tested using a Fisher's Exact test (p < 0.05), based on the number of significantly regulated genes from the cross-study analysis within each GO term. Each GO term with number of genes between 10 and 500 were retained in the cross-study analysis. Additional information about cross-study analysis can be found at the SMRI online genomics database http://www.stanleygenomics.org/cross.html. The false discovery rate (FDR) was calculated based on the ratio of expected number of genes by chance at the specific p-value threshold (e.g. at p = 0.0001 and 19,502 genes = expect 2 genes by chance) divided by the sum of the expected number of genes by chance and the actual number of genes obtained at that threshold.
NCBI's Database for Annotation, Visualization and Integrated Discovery (DAVID 2007) was used as the standard source for gene annotation information . The primary fields extracted from the DAVID include: Entrez ID, gene symbol, gene name and gene summary. Additional annotations include gene product mappings to the GO Consortium for the GO terms/classes. For microarrays, queries were based on the Affymetrix probe set ID (AFFYID).
Real-time quantitative PCR
Total RNA was extracted from the dorsolateral prefrontal cortex tissues (BA46) of the Array Collection (psychosis N = 56, non-psychosis N = 49). RNA was further purified with the PureLink Micro to Midi Total RNA Purification System (Invitrogen, Carlsbad, CA) and the quality of RNA was assessed with the Bioanalyzer 2100 (Agilent, Foster City, CA). cDNA was synthesized with RT-PCR using oligo dT primers (Super Script III, Invitrogen, Carlsbad, CA). For real-time PCR, 1 μl aliquots of validated QuantiTect SYBR primer (Qiagen, Valencia, CA), 10 μl qPCR Master mix (Applied Biosystems, Foster City, CA), and 10 μl diluted cDNA were mixed together and pipetted into single wells of the qPCR plate (384-well format) with the Prism7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). For no template controls for each gene tested, water was added instead of the cDNA. Thermo cycle conditions were: (1) 1 cycle for 2 min at 50°C, (2) 1 cycle for 15 min at 95°C, and (3) 40 cycles for 15 sec at 95°C and 1 min at 60°C and fluorescence was measured during the 60°C step for each cycle as recommended by the manufacturer. Reactions were quantified by the delta delta cycle threshold (Ct) method using SDS2.2 software (Applied Biosystems, Foster City, CA) generating a mean quantity value (Qty mean) for each sample from the triplicates of that sample for each gene. Recent studies have shown an advantage of using multiple endogenous control genes for the qPCR experiment , and therefore we used three endogenous control genes including β-2 microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB) in the qPCR experiment. The data for each gene of interest was expressed as Qty mean for the gene of interest/geometric mean of Qty mean values for the three endogenous control genes. Normalized values were then expressed as fold changes between the psychosis and the non-psychosis control group.
Summary of subject characteristics in the studies included in the cross-study analysis of psychosis
# of Samples (Subjects)
43.9 +/- 10.2
6.49 +/- .32
6.34 +/- .28
31.0 +/- 15.8
32.9 +/- 15.7
Smoking at TOD
Heavy Drug Use
Heavy Alcohol Use
Summary of the seven microarray studies included in the cross-study analysis of psychosis
Affy hgu133 2.0+
Affy hgu133 2.0+
Demographic and clinical variable analysis in individual studies
Median % Regulated in Individual Studies
Heavy Alcohol Use
Heavy Drug Use
Agonal State (Sudden Death)
Mood Stabilizer Use
Summary of cross-study analysis of psychosis showing fold changes and p-values.
Psychosis Combined Analysis
In the current study, we have found the genes that are differentially regulated in the prefrontal cortex of individuals with psychosis. These findings are important because we performed a cross-study analysis of seven microarray studies that used three different Affymetrix platforms with two different post-mortem brain collections. Therefore, these gene expression changes are "consensus" fold changes across multiple microarray studies following adjustment of confounding variables in individual studies.
It is well known that gene expression studies of psychiatric disorders using post-mortem brains are more challenging than others [25–28]. Possible reasons for this complexity include pre- and post-mortem factors such as RNA quality, brain pH, PMI and agonal state that affect gene expression patterns in the brains of psychiatric patients . Moreover, biological and disease-specific effects are often hindered by several issues such as relatively small sample sizes, small effect sizes and heterogeneity of psychiatric phenotypes in the general population. The clinical information available for the patients is typically sparse, so that unknown clinical covariates may either confound or confuse many of the gene expression findings in psychiatric disorders . Therefore, appropriate statistical adjustment using such demographic and clinical information is critical in order to improve inferences in determining putative genes and biological pathways in psychiatric disorders.
Gene expression microarray technology has become a powerful tool for discovery, although this technology had some limitations such as high cost of experiments, limited sample size, and lack of standardization on data analysis. Recently, there have been improvements in the microarray field, and more microarray datasets are available for meta-analysis. Several studies have described important issues related to the meta-analysis of microarray data including standardization, statistical analysis and databasing strategy , and the development of new bioinformatic tools such as searchable online archives of genetic/genomic findings in psychiatric disorders . One of the main advantages of meta-analysis as compared to an individual study is the increased statistical power to detect consensus fold changes across multiple studies. It has been reported that gene expression changes in post-mortem brains of psychiatric patients are relatively small. This may explain some of the discrepancies in previous studies that reported putative genes in psychiatric disorders, because most of the studies were not sufficiently powered (due to small sample sizes) to detect small changes in gene expression. Moreover, some studies did not have sufficient clinical information of post-mortem brains to adjust for possible confounding variables.
In the current analysis, we have included seven microarray studies that used the frontal cortex (BA46/10, BA8/9 and BA6) as compared to the previous study  that included the cerebellum studies. A recent study demonstrated that different brain regions such as the frontal, cingulate, temporal, parietal, occipital cortices, hippocampus and sub-cortical regions show different patterns of gene expression . The authors also found that gene expression patterns in the prefrontal cortices (BA10 and BA46) are similar to each other as compared to non-frontal regions. To our knowledge, there is little evidence on gene expression differences in the sub-regions of the frontal cortex because most studies have focused on one region of the frontal cortex of schizophrenia patients. Another limitation was an availability of the prefrontal cortex (BA46) tissues from the Neuropathology Consortium when individual microarray studies were conducted. This brain cohort has been used by many investigators for various types of research in the past. Therefore, we included 3 studies that used the frontal cortices (BA46/10, BA8/9 and BA6) from the Neuropathology Consortium because these regions are adjacent to each other and have been implicated in schizophrenia [32–34]. Nevertheless, we included another 4 studies that used the Array Collection with the same dorsolateral prefrontal cortex (BA46).
In the current cross-study analysis, we identified a set of metallothionein genes including MT1X, MT1K, MT1E, MT1H, MT1F, MT2A and MT3 that are significantly up-regulated in psychosis. We used a real-time qPCR to validate differential expression of metallothionein genes in the prefrontal cortex (BA46) of psychosis patients. Real-time qPCR is often referred as the gold standard for validation of gene expression in microarrays due to its advantages in detection sensitivity, large scale dynamic range, high precision and reproducible quantitation compared to other techniques [35, 36]. For the qPCR, we used a complete set of dorsolateral prefrontal cortex (BA46) tissues from the Array Collection (psychosis N = 56, non-psychosis N = 49). It is important to note that most previous microarray studies have used a relatively small number of post-mortem brains for the qPCR validation.
Although metallothioneins were discovered almost 50 years ago, their functional role in the brain has not been well-characterized. Putative physiological functions of metallothioneins in the CNS, including neuroprotection, regeneration and cognitive function, have been described in a recent paper . Other studies reported that metallothioneins are involved in cellular host defense response, stress response, immunoregulation, cell survival and brain repair [38–41]. Astrocytes appear to be the main source of metallothioneins in the brain, even though the primary function of metallothioneins are protecting neurons from a variety of pathology . Increased MT1 and MT2 gene expression have been reported in several types of brain pathology including traumatic and excitotoxic injury, amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease [43–47]. Studies using animal models showed that metallothioneins may be involved in behavior associated with substance dependence  and learning and memory . Similar to our findings, one study reported that MT2A gene expression is increased in the PFC of schizophrenia patients . These results suggest that metallothioneins in the brain may play a significant role in neuroprotection and cognitive function. It is possible that neurodegenerative process may disrupt cognitive function in the frontal cortex of psychosis patients and up-regulation of metallothionein genes in the PFC may be a compensatory mechanism against these adverse processes. Interestingly, a recent study reported that metallothionein-related compounds are well tolerated in animal studies , and therefore, these compounds may be potential candidates for novel medication development in psychosis-related disorders.
The genes down-regulated in psychosis include neuropeptide genes such as somatostatin (SST), neuropeptide Y (NPY) and tachykinin (TAC1). The neuropeptide genes have been implicated in working memory function and in schizophrenia . The NPY gene may be associated with schizophrenia , impulsivity , aggression and bipolar disorders [54, 55]. Previous studies reported decreased NPY levels in the temporal cortex of schizophrenia  and decreased NPY receptor gene expression in lymphocytes of schizophrenia . Gabriel et al reported that both NPY and SST levels are decreased in the cerebral cortex of individuals with schizophrenia . A microarray study reported that SST gene expression is increased in the PFC of bipolar disorder but not with schizophrenia patients . It is possible that this study may not have been sufficiently powered (due to small sample sizes) to detect small gene expression changes in schizophrenia. Consistent to the current results, mRNA levels of SST in the PFC are decreased in schizophrenia patients in a study using in situ hybridization  and another microarray study reported that both SST and NPY expression levels are decreased in the PFC of schizophrenia . TAC1-related genes are also implicated in psychiatric disorders [61, 62] and increased protein levels of TAC1 receptor in the PFC of schizophrenia have been reported . Taken together, previous findings and the current results provide strong evidence for involvement of neuropeptide genes in psychosis-related disorders.
One of the potential confounding variables affecting neuropeptide gene expression may be the antipsychotic medication. Previous studies reported that NPY levels in the brain are affected by various drugs including typical and atypical antipsychotics [64, 65]. Using rodents, one study reported that NPY and SST levels are increased in the PFC following haloperidol treatment , while another study reported that NPY levels are decreased following chronic antipsychotic treatment . However, GABA-system related genes including SST are not changed in the PFC of monkey brains treated with chronic antipsychotic drugs . In order to minimize the confounding effect of antipsychotic medication from the disease effect, we used multiple regression models to adjust antipsychotic medication in the current analysis.
Another gene down-regulated in psychosis is the transcription factor Nurr1 (NR4A2), an orphan nuclear receptor associated with the development of dopaminergic cells in the mid-brain (p < 0.00001, FC-1.16). This gene has been implicated in attention deficit hyperactivity disorder, alcohol dependence, schizophrenia and bipolar disorder [68–70]. A recent study with NR4A2 knock-out mice suggests that these animals display behavioral endophenotypes that are displayed in other animal models of psychosis/schizophrenia. . Therefore, reduced NR4A2 gene expression in the PFC may be associated with psychotic features.
Although genome-wide gene expression profiling in the postmortem brains may reveal valuable information related to psychiatric disorders, this approach alone is limited in terms of being able to distinguish between changes reflecting the primary disease etiology from those reflecting compensatory mechanisms and many potential confounding influences such as medications and drug use . Therefore, it is necessary to study the relationship between gene expression, genetic and epigenetic variations in individuals with psychiatric disorders. The integration of postmortem gene expression with genetic variations including single nucleotide polymorphisms (SNPs) is the subject of ongoing investigations.
We found a set of genes that are differentially regulated in the prefrontal cortex of individuals with psychosis. Among those genes, metallothionein genes are consistently up-regulated and neuropeptide genes are down-regulated. These genes may have implications in neurodegeneration and working memory function in the prefrontal cortex that are thought to be disrupted in psychosis. With an advantage of cross-study analysis, we were able to detect small but "consensus" changes in gene expression across multiple microarray studies. By combining gene expression analyses across multiple microarray studies and with the qPCR validation of putative genes, we can provide greater confidence in the scientific findings, which include potential genes and biological pathways in psychiatric disorders, as compared to the result obtained from a single study.
We would like to thank the SMRI collaborators who contributed their microarray data for the cross-study analysis: Drs. C. Anthony Altar, Sabine Bahn, Haiming Chen, Seth E Dobrin, Tadafumi Kato and Pamela Sklar.
- Jablensky A: The conflict of the nosologists: views on schizophrenia and manic-depressive illness in the early part of the 20th century. Schizophr Res. 1999, 39 (2): 95-100. 10.1016/S0920-9964(99)00106-1. discussion 159.View ArticlePubMedGoogle Scholar
- Ovsiew F: An end to Kraepelinian nosology?. J Neuropsychiatry Clin Neurosci. 2000, 12 (3): 297-299.View ArticlePubMedGoogle Scholar
- Crow TJ: The continuum of psychosis and its genetic origins. The sixty-fifth Maudsley lecture. Br J Psychiatry. 1990, 156: 788-797. 10.1192/bjp.156.6.788.View ArticlePubMedGoogle Scholar
- Taylor MA: Are schizophrenia and affective disorder related? A selective literature review. Am J Psychiatry. 1992, 149 (1): 22-32.View ArticlePubMedGoogle Scholar
- Taylor MA, Amir N: Are schizophrenia and affective disorder related?: the problem of schizoaffective disorder and the discrimination of the psychoses by signs and symptoms. Compr Psychiatry. 1994, 35 (6): 420-429. 10.1016/0010-440X(94)90224-0.View ArticlePubMedGoogle Scholar
- Torrey EF, Miller J, Rawlings R, Yolken RH: Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res. 1997, 28 (1): 1-38. 10.1016/S0920-9964(97)00092-3.View ArticlePubMedGoogle Scholar
- Torrey EF: Epidemiological comparison of schizophrenia and bipolar disorder. Schizophr Res. 1999, 39 (2): 101-106. 10.1016/S0920-9964(99)00107-3. discussion 159–160.View ArticlePubMedGoogle Scholar
- Craddock N, O'Donovan MC, Owen MJ: Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull. 2006, 32 (1): 9-16. 10.1093/schbul/sbj033.View ArticlePubMedGoogle Scholar
- Owen MJ, Craddock N, Jablensky A: The genetic deconstruction of psychosis. Schizophr Bull. 2007, 33 (4): 905-911. 10.1093/schbul/sbm053.View ArticlePubMedPubMed CentralGoogle Scholar
- Ivleva E, Thaker G, Tamminga CA: Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr Bull. 2008, 34 (4): 734-742. 10.1093/schbul/sbn051.View ArticlePubMedPubMed CentralGoogle Scholar
- Goes FS, Sanders LL, Potash JB: The genetics of psychotic bipolar disorder. Curr Psychiatry Rep. 2008, 10 (2): 178-189. 10.1007/s11920-008-0030-5.View ArticlePubMedGoogle Scholar
- Pearlson GD, Folley BS: Endophenotypes, dimensions, risks: is psychosis analogous to common inherited medical illnesses?. Clin EEG Neurosci. 2008, 39 (2): 73-77.View ArticlePubMedGoogle Scholar
- Glahn DC, Bearden CE, Cakir S, Barrett JA, Najt P, Serap Monkul E, Maples N, Velligan DI, Soares JC: Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disord. 2006, 8 (2): 117-123. 10.1111/j.1399-5618.2006.00296.x.View ArticlePubMedGoogle Scholar
- Krabbendam L, Arts B, van Os J, Aleman A: Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005, 80 (2–3): 137-149. 10.1016/j.schres.2005.08.004.View ArticlePubMedGoogle Scholar
- Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB: Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry. 2005, 57 (3): 252-260. 10.1016/j.biopsych.2004.10.019.View ArticlePubMedGoogle Scholar
- Baumann B, Bogerts B: The pathomorphology of schizophrenia and mood disorders: similarities and differences. Schizophr Res. 1999, 39 (2): 141-148. 10.1016/S0920-9964(99)00113-9. discussion 162.View ArticlePubMedGoogle Scholar
- Strasser HC, Lilyestrom J, Ashby ER, Honeycutt NA, Schretlen DJ, Pulver AE, Hopkins RO, Depaulo JR, Potash JB, Schweizer B, et al: Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study. Biol Psychiatry. 2005, 57 (6): 633-639. 10.1016/j.biopsych.2004.12.009.View ArticlePubMedGoogle Scholar
- Torrey EF, Webster M, Knable M, Johnston N, Yolken RH: The stanley foundation brain collection and neuropathology consortium. Schizophr Res. 2000, 44 (2): 151-155. 10.1016/S0920-9964(99)00192-9.View ArticlePubMedGoogle Scholar
- Jones L, Goldstein DR, Hughes G, Strand AD, Collin F, Dunnett SB, Kooperberg C, Aragaki A, Olson JM, Augood SJ, et al: Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinformatics. 2006, 7: 211-10.1186/1471-2105-7-211.View ArticlePubMedPubMed CentralGoogle Scholar
- Higgs BW, Elashoff M, Richman S, Barci B: An online database for brain disease research. BMC Genomics. 2006, 7: 70-10.1186/1471-2164-7-70.View ArticlePubMedPubMed CentralGoogle Scholar
- Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF: Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci. 2007, 31 (3): 221-243.PubMedGoogle Scholar
- Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4 (5): P3-10.1186/gb-2003-4-5-p3.View ArticlePubMedGoogle Scholar
- Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM, Kleinman JE: Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry. 2006, 60 (6): 650-658. 10.1016/j.biopsych.2006.06.019.View ArticlePubMedGoogle Scholar
- Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24 (9): 1151-1161. 10.1038/nbt1239.View ArticlePubMedGoogle Scholar
- Iwamoto K, Kato T: Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist. 2006, 12 (4): 349-361. 10.1177/1073858406287536.View ArticlePubMedGoogle Scholar
- Miklos GL, Maleszka R: Microarray reality checks in the context of a complex disease. Nat Biotechnol. 2004, 22 (5): 615-621. 10.1038/nbt965.View ArticlePubMedGoogle Scholar
- Mirnics K, Levitt P, Lewis DA: Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry. 2006, 60 (2): 163-176. 10.1016/j.biopsych.2006.02.003.View ArticlePubMedGoogle Scholar
- Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC: Gene expression profiling in the post-mortem human brain – no cause for dismay. J Chem Neuroanat. 2001, 22 (1–2): 79-94. 10.1016/S0891-0618(01)00099-0.View ArticlePubMedGoogle Scholar
- Cahan P, Rovegno F, Mooney D, Newman JC, St Laurent G, McCaffrey TA: Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene. 2007, 401 (1–2): 12-18. 10.1016/j.gene.2007.06.016.View ArticlePubMedPubMed CentralGoogle Scholar
- Konneker T, Barnes T, Furberg H, Losh M, Bulik CM, Sullivan PF: A searchable database of genetic evidence for psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet. 2008Google Scholar
- Katsel P, Davis KL, Gorman JM, Haroutunian V: Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res. 2005, 77 (2–3): 241-252. 10.1016/j.schres.2005.03.020.View ArticlePubMedGoogle Scholar
- Koch K, Wagner G, Nenadic I, Schachtzabel C, Roebel M, Schultz C, Axer M, Reichenbach JR, Sauer H, Schlosser RG: Temporal modeling demonstrates preserved overlearning processes in schizophrenia: an fMRI study. Neuroscience. 2007, 146 (4): 1474-1483. 10.1016/j.neuroscience.2007.03.021.View ArticlePubMedGoogle Scholar
- Digney A, Keriakous D, Scarr E, Thomas E, Dean B: Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry. 2005, 57 (7): 711-715. 10.1016/j.biopsych.2004.12.028.View ArticlePubMedGoogle Scholar
- Dean B, Keriakous D, Scarr E, Thomas EA: Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust N Z J Psychiatry. 2007, 41 (4): 308-320. 10.1080/00048670701213245.View ArticlePubMedGoogle Scholar
- Morey JS, Ryan JC, Van Dolah FM: Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online. 2006, 8: 175-193. 10.1251/bpo126.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L, Samaha RR: Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics. 2006, 7: 59-10.1186/1471-2164-7-59.View ArticlePubMedPubMed CentralGoogle Scholar
- West AK, Hidalgo J, Eddins D, Levin ED, Aschner M: Metallothionein in the central nervous system: Roles in protection, regeneration and cognition. Neurotoxicology. 2008Google Scholar
- Haq F, Mahoney M, Koropatnick J: Signaling events for metallothionein induction. Mutat Res. 2003, 533 (1–2): 211-226.View ArticlePubMedGoogle Scholar
- Penkowa M: Metallothioneins are multipurpose neuroprotectants during brain pathology. Febs J. 2006, 273 (9): 1857-1870. 10.1111/j.1742-4658.2006.05207.x.View ArticlePubMedGoogle Scholar
- Ebadi M, Iversen PL, Hao R, Cerutis DR, Rojas P, Happe HK, Murrin LC, Pfeiffer RF: Expression and regulation of brain metallothionein. Neurochem Int. 1995, 27 (1): 1-22. 10.1016/0197-0186(94)00164-P.View ArticlePubMedGoogle Scholar
- Natale JE, Knight JB, Cheng Y, Rome JE, Gallo V: Metallothionein I and II mitigate age-dependent secondary brain injury. J Neurosci Res. 2004, 78 (3): 303-314. 10.1002/jnr.20265.View ArticlePubMedGoogle Scholar
- West AK, Chuah MI, Vickers JC, Chung RS: Protective role of metallothioneins in the injured mammalian brain. Rev Neurosci. 2004, 15 (3): 157-166.View ArticlePubMedGoogle Scholar
- Ogra Y, Suzuki KT: Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol Biol (Noisy-le-grand). 2000, 46 (2): 357-365.Google Scholar
- Hidalgo J, Aschner M, Zatta P, Vasak M: Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull. 2001, 55 (2): 133-145. 10.1016/S0361-9230(01)00452-X.View ArticlePubMedGoogle Scholar
- Nagano S, Satoh M, Sumi H, Fujimura H, Tohyama C, Yanagihara T, Sakoda S: Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur J Neurosci. 2001, 13 (7): 1363-1370. 10.1046/j.0953-816x.2001.01512.x.View ArticlePubMedGoogle Scholar
- Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martinez Caceres EM: Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci. 2003, 60 (6): 1258-1266.PubMedGoogle Scholar
- Dittmann J, Fung SJ, Vickers JC, Chuah MI, Chung RS, West AK: Metallothionein biology in the ageing and neurodegenerative brain. Neurotox Res. 2005, 7 (1–2): 87-93.View ArticlePubMedGoogle Scholar
- Loney KD, Uddin KR, Singh SM: Strain-specific brain metallothionein II (MT-II) gene expression, its ethanol responsiveness, and association with ethanol preference in mice. Alcohol Clin Exp Res. 2003, 27 (3): 388-395. 10.1097/01.ALC.0000056613.00588.7C.View ArticlePubMedGoogle Scholar
- Levin ED, Perraut C, Pollard N, Freedman JH: Metallothionein expression and neurocognitive function in mice. Physiol Behav. 2006, 87 (3): 513-518. 10.1016/j.physbeh.2005.11.014.View ArticlePubMedGoogle Scholar
- Arion D, Unger T, Lewis DA, Levitt P, Mirnics K: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2007, 62 (7): 711-721. 10.1016/j.biopsych.2006.12.021.View ArticlePubMedPubMed CentralGoogle Scholar
- Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics K, Lewis DA: Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2008, 13 (2): 147-161. 10.1038/sj.mp.4002011.View ArticlePubMedGoogle Scholar
- Ikeda K, Ikeda K, Iritani S, Ueno H, Niizato K: Distribution of neuropeptide Y interneurons in the dorsal prefrontal cortex of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004, 28 (2): 379-383. 10.1016/j.pnpbp.2003.11.008.View ArticlePubMedGoogle Scholar
- Greco B, Carli M: Reduced attention and increased impulsivity in mice lacking NPY Y2 receptors: relation to anxiolytic-like phenotype. Behav Brain Res. 2006, 169 (2): 325-334. 10.1016/j.bbr.2006.02.002.View ArticlePubMedGoogle Scholar
- Karl T, Herzog H: Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides. 2007, 28 (2): 326-333. 10.1016/j.peptides.2006.07.027.View ArticlePubMedGoogle Scholar
- Kuromitsu J, Yokoi A, Kawai T, Nagasu T, Aizawa T, Haga S, Ikeda K: Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res Gene Expr Patterns. 2001, 1 (1): 17-21. 10.1016/S1567-133X(01)00003-5.View ArticlePubMedGoogle Scholar
- Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S: Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand. 1991, 83 (4): 273-277. 10.1111/j.1600-0447.1991.tb05539.x.View ArticlePubMedGoogle Scholar
- Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, Byerley W: Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res. 2004, 67 (1): 41-52. 10.1016/S0920-9964(03)00151-8.View ArticlePubMedGoogle Scholar
- Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL: Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996, 39 (2): 82-91. 10.1016/0006-3223(95)00066-6.View ArticlePubMedGoogle Scholar
- Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I, Kato T, Osumi N, Higuchi T, Niwa S, et al: Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet. 2006, 15 (12): 1949-1962. 10.1093/hmg/ddl118.View ArticlePubMedGoogle Scholar
- Morris HM, Hashimoto T, Lewis DA: Alterations in Somatostatin mRNA Expression in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia or Schizoaffective Disorder. Cereb Cortex. 2008Google Scholar
- Chahl LA: Tachykinins and neuropsychiatric disorders. Curr Drug Targets. 2006, 7 (8): 993-1003. 10.2174/138945006778019309.View ArticlePubMedGoogle Scholar
- Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE, Edenberg HJ, Kuczenski R, Geyer MA, Nurnberger JI, et al: Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet. 2007, 144 (2): 129-158.View ArticleGoogle Scholar
- Tooney PA, Crawter VC, Chahl LA: Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2001, 49 (6): 523-527. 10.1016/S0006-3223(00)01068-4.View ArticlePubMedGoogle Scholar
- Obuchowicz E, Krysiak R, Herman ZS: Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs?. Neurosci Biobehav Rev. 2004, 28 (6): 595-610. 10.1016/j.neubiorev.2004.08.006.View ArticlePubMedGoogle Scholar
- Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J: The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol. 2003, 18 (7): 551-557. 10.1002/hup.519.View ArticlePubMedGoogle Scholar
- Sakai K, Maeda K, Chihara K, Kaneda H: Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides. 1995, 29 (3): 157-161. 10.1016/0143-4179(95)90018-7.View ArticlePubMedGoogle Scholar
- Huang XF, Deng C, Zavitsanou K: Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides. 2006, 40 (3): 213-219. 10.1016/j.npep.2006.01.002.View ArticlePubMedGoogle Scholar
- Chen YH, Tsai MT, Shaw CK, Chen CH: Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am J Med Genet. 2001, 105 (8): 753-757. 10.1002/ajmg.10036.View ArticlePubMedGoogle Scholar
- Smith KM, Bauer L, Fischer M, Barkley R, Navia BA: Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2005, 133 (1): 57-63.View ArticleGoogle Scholar
- Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T: Mutation analysis of the retinoid × receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence. Am J Med Genet. 2002, 114 (1): 15-23. 10.1002/ajmg.1620.View ArticlePubMedGoogle Scholar
- Rojas P, Joodmardi E, Hong Y, Perlmann T, Ogren SO: Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry. 2007, 12 (8): 756-766. 10.1038/sj.mp.4001993.View ArticlePubMedGoogle Scholar
- Bray NJ: Gene expression in the etiology of schizophrenia. Schizophr Bull. 2008, 34 (3): 412-418. 10.1093/schbul/sbn013.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-244X/8/87/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.